Ayub Medical College

Neurocritical care patients, including those with traumatic brain injury, subarachnoid hemorrhage, and intracerebral hemorrhage, often develop anemia, compromising brain oxygen delivery and increasing morbidity and mortality. Blood transfusion strategies, either liberal or restrictive, are commonly used to manage anemia in these patients, but the optimal approach remains unclear due to mixed results in existing studies.

A systematic search of PubMed, Cochrane Library, ScienceDirect, and Google Scholar from inception to December 2024 for randomized controlled trials (RCTs) evaluating restrictive versus liberal transfusion strategies in adult neurocritical care patients. Outcomes included mortality, Glasgow Outcome Scale (GOS), red blood cell (RBC) units transfused, sepsis, intensive care unit (ICU)/hospital length of stay, and secondary complications. The study is registered with PROSPERO (CRD42025635426).

The analysis included seven RCTs with 1941 patients. The restrictive strategy significantly reduced the number of RBC units transfused per patient (MD: 2.36; 95% CI: 1.08–3.64; p = 0.0003) and was associated with a lower incidence of sepsis (RR: 0.73; 95% CI: 0.56–0.96; p = 0.02). There were no significant differences between restrictive and liberal strategies for ICU (RR 0.74; 95% CI 0.28–1.91; p = 0.53), in‐hospital (RR 0.77; 95% CI 0.35–1.68), 30‐day (RR 0.91; 95% CI 0.70–1.18), 6‐month (RR 0.98; 95% CI 0.67–1.44), or long‐term mortality (RR 1.00; 95% CI 0.80–1.24). GOS scores at 6 months showed no significant difference (RR 0.94; 95% CI 0.83–1.07). ICU and hospital length of stay were also comparable between strategies. Secondary outcomes, including stroke, brain hypoxia, intracranial hypertension, and other non‐neurological complications, showed no significant differences between the two strategies.

Restrictive transfusion strategies are as effective as liberal strategies in terms of mortality and neurological complications, with additional benefits such as fewer RBC transfusions and lower sepsis rates. These findings support restrictive strategies as a safer approach to managing anemia in neurocritical care, though further research on long‐term outcomes is needed.

Regenerative medicine offers hope to close the gap between organ failure and transplant availability, but progress remains incremental. This editorial reviews early clinical triumphs, such as cultured skin grafts and tissue-engineered bladders and vaginas, and contrasts them with persistent barriers to whole-organ replacement. We examine stem cell interventions that show functional gains in small trials (for example, cardiopoietic cells and stem-cell-derived islets) yet lack long-term evidence, consistent manufacturing, and proven survival benefit. Tissue engineering advances, including decellularization, perfusion bioreactors, and three-dimensional bioprinting, demonstrate feasibility for simple constructs but fall short for complex organs that require integrated vasculature and multiple specialized cell types. We highlight safety concerns such as thromboembolism and fibrosis, variable product quality, and the risk posed by unregulated clinics. Ethical, regulatory, and economic obstacles, including unclear approval pathways, absent long-term registries, high costs, and potential inequities, threaten translation. To advance patient-centered care, we call for rigorous and transparent clinical trials, shared manufacturing standards, mandatory long-term follow-up, and multidisciplinary collaboration focused on near-term clinically impactful strategies alongside long-term organ engineering research. Humility, vigilance, and alignment of innovation with clinical need are essential if lab-grown organs are to become safe and equitable therapies.